Jane Street’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-140,600
| Closed | -$2.53M | – | 8368 |
|
|
2020
Q2 | $2.53M | Buy |
140,600
+58,300
| +71% | +$811K | ﹤0.01% | 2740 |
|
|
2020
Q1 | $587K | Sell |
82,300
-27,000
| -25% | -$337K | ﹤0.01% | 3450 |
|
|
2019
Q4 | $2.61M | Buy |
+109,300
| New | +$3.02M | ﹤0.01% | 1652 |
|
|
2018
Q3 | – | Sell |
-8,700
| Closed | -$329K | – | 5989 |
|
|
2018
Q2 | $329K | Sell |
8,700
-9,100
| -51% | -$348K | ﹤0.01% | 4027 |
|
|
2018
Q1 | $581K | Buy |
17,800
+11,800
| +197% | +$518K | ﹤0.01% | 3314 |
|
|
2017
Q4 | $292K | Buy |
6,000
+400
| +7% | +$20.2K | ﹤0.01% | 3797 |
|
|
2017
Q3 | $303K | Sell |
5,600
-68,100
| -92% | -$4M | ﹤0.01% | 3676 |
|
|
2017
Q2 | $4.14M | Buy |
+73,700
| New | +$2.95M | 0.01% | 892 |
|
|
2017
Q1 | – | Sell |
-23,800
| Closed | -$534K | – | 4899 |
|
|
2016
Q4 | $534K | Buy |
+23,800
| New | +$465K | ﹤0.01% | 2794 |
|
|
2016
Q2 | – | Sell |
-36,800
| Closed | -$751K | – | 4807 |
|
|
2016
Q1 | $751K | Buy |
36,800
+31,600
| +608% | +$1M | ﹤0.01% | 2144 |
|
|
2015
Q4 | $268K | Buy |
+5,200
| New | +$252K | ﹤0.01% | 3242 |
|
Jane Street's PTLA Position: Q2 2020 in Review
Jane Street sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 96,746 shares — an estimated $1.35M sold.
Jane Street first reported a position in PTLA in Q2 2013 and held it in 20 quarters. The position peaked at $2.61M in Q2 2017. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.
- Jane Street reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
- Jane Street sold 96,746 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $1.35M.
- Jane Street first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 20 quarters.
- Jane Street's Portola Pharmaceuticals, Inc. position peaked at $2.61M in Q2 2017.
- 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.
Based on Jane Street's 13F filing for Q2 2020, filed 17 Aug 2020.